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Genomic tools have evolvedwith remarkable rapidity, but their clinical relevance and application have lagged
behind. Now, consistent clinical applications have finally arrived and bring with them the promise of
identifying the underlying causes of complex neurological disorders in a patient-specific manner.Since the origin of large-scale genomics,
two primary motivations have been to
connect genetic variation to diseases
and outcomes in order to identify vali-
dated drug targets (Manolio et al., 2008)
and to subclassify patients into groups
relevant to treatment. These ambitions
have been partly realized. Genetic
studies have indeed led directly to drug
development programs with the poten-
tial for wide therapeutic application. For
example, mutations in PCSK9, encoding
proprotein convertase subtilisin kexin-9
(PCSK9), were first identified in a family
exhibiting hypercholesterolemia. Loss-
of-function alleles were later shown to
lead to reduced low-density lipoprotein
(LDL) cholesterol and protect against car-
diovascular disease without any adverse
effects. Thus, genetic insights from pa-
tients told drug developers that PCSK9
inhibition may be an effective new tool
in cholesterol management (Wierzbicki
et al., 2012). Another example is SOST,
encoding the protein sclerostin, a critical
inhibitor of bone formation. Mutations in
this gene are associated with a rare
bone disorder, and modulation of normal
sclerostin function (via specific mono-
clonal antibodies) may play a role in the
treatment of common bone disorders
such as osteoporosis (Paszty et al., 2010).
Despite these promising translational
developments, the indispensable geno-
mic application of the moment is argu-
ably not in charging the pipelines of big
pharma, but rather in diagnosing genetic
conditions that are difficult to elucidate.
Clinical genetics is a field that has tradi-
tionally focused on individual gene tests
indicated by the specific clinical pre-
sentation. Recently, steps toward morecomprehensive assessments have been
made, including both disease-related
gene panels and array-based technology
for detecting genome-wide copy-number
variation; these offer higher resolution
than traditional karyotype analysis. The
culmination of these steps toward more
comprehensive assessment, however,
is clearly next-generation sequencing
(NGS). The era of comprehensive NGS
in clinical genetics began with diagnostic
reports appearing in late 2009 (Choi
et al., 2009) and early 2010 (Ng et al.,
2010) in the form of whole-exome
sequencing (WES).
Some recent examples of WES in
clinical diagnosis include an infant of
consanguinous parents with failure to
thrive and dehydration, who was diag-
nosed with congenital chloride diarrhea
due to a homozygous missense mutation
in the SLC26A3 gene (Choi et al., 2009).
Similarly, a compound heterozygote
mutation in the DHODH gene was dis-
covered in four affected individuals in
three independent kindreds as a cause
of a multiple-malformation disorder,
Miller syndrome, a disorder that had
previously been intractable to more tradi-
tional approaches of discovery (Ng et al.,
2010). In addition to new disease gene
discovery, WES may also be useful in
refining clinical therapeutic decisions in
individual patients, as exemplified by
the beneficial addition of 5-hydroxytrpto-
phan (a serotonin precursor) to L-dopa
therapy in two twins with dopa-respon-
sive dystonia (Bainbridge et al., 2011).
Another illustrative case is that of a
young boy with a severe Crohn’s disease
phenotype who was found by exome
sequencing to have a novel, hemizygousNeuron 80, Nmissense mutation in the X-linked inhi-
bitor of apoptosis gene and who went
on to do well following an allogeneic
hematopoietic progenitor cell transplant
(Worthey et al., 2011). Furthermore, in a
recent pilot program of WES in 12 pa-
tients with unexplained and apparently
genetic conditions, a specific genetic
diagnosis was made in half of the pa-
tients (Need et al., 2012).
Despite some encouraging examples,
however, successful diagnoses will not
always, or even (at present) often, lead
to improved treatments. The reality is
that the majority of known Mendelian
diseases cannot be effectively treated,
at least as of yet. Nevertheless, the
importance to affected families of receiv-
ing a specific, correct diagnosis after
years of uncertainty and soul searching
cannot be overstated. Individuals with
intellectual disability and epilepsy often
require full-time care from a young age,
the burden of which falls on the parents
and family. It is extraordinary to witness
the dedication and love that families
show in caring for individuals with com-
plex neurological deficits and needs
over many years. For them, simply
knowing the real explanation for the un-
derlying disorder can provide comfort,
reassurance, and closure. The correct
diagnosis can also facilitate the provision
of appropriate state health and social
services. Of course, the hope is that
knowing the correct diagnosis will also
allow a more targeted approach to future
therapies as they are discovered. Early
application of NGS can bring to a close
an often previously tedious, expensive,
and emotionally wrenching ‘‘diagnostic
odyssey’’; for all of the reasons listedovember 20, 2013 ª2013 Elsevier Inc. 841
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medical practice.
There are likely few therapeutic areas
set to benefit more from this new para-
digm in clinical genetics than neurological
disorders, particularly those affecting
children. There are several intercon-
nected reasons for this: much of neuro-
logical illness has already been shown to
have a genetic basis; it is often difficult
to predict the genetic defect on clinical
grounds; new causative variants are be-
ing described weekly; and it is expensive
and burdensome to test on a gene-by-
gene basis. In addition, the global burden
of unexplained neurological disorders
is immense. Epilepsy alone affects 6o
million people worldwide, and the diag-
nosis of epilepsy encompasses a large
group of brain disorders characterized
by the occurrence of recurrent unpro-
voked seizures; one third of these individ-
uals have medically refractory, poorly
controlled seizures. Although there may
be a recognized proximate cause in an
individual patient (e.g., traumatic brain
injury), in about 50% of those with epi-
lepsy, no known etiology is apparent.
It is likely that a large proportion of these
individuals have an underlying genetic
underpinning to their epilepsy. Many
may be due to individual mutations
affecting a variety of proteins and path-
ways necessary for normal brain develop-
ment and function.
Similarly, 1%–3% of the population has
a lifelong intellectual disability (ID; from
mild to profound) with associated sig-
nificant long-term personal, family, social,
and economic consequences. Again, the
etiology of intellectual disability is un-
known in about half of individuals. Recent
evidence confirms that, as with epilepsy,
the underlying causes of ID are mole-
cularly diverse, with a significant pro-
portion accounted for by functionally
deleterious de novo mutations across a
spectrum of genes (de Ligt et al., 2012;
Rauch et al., 2012). Moreover, there
is overlap between epilepsy and ID,
whereby one third of individuals with ID
have epilepsy as a manifestation of their
underlying brain disorder, and approxi-
mately 20% of patients attending a
tertiary referral epilepsy clinic have an
associated intellectual disability. A recent
study has shown that de novo mutations
are important as a cause of previously842 Neuron 80, November 20, 2013 ª2013 Eunexplained childhood epileptic enceph-
alopathies, conditions generally associ-
ated with severe epilepsy and intellectual
disability (Allen et al., 2013).
It is becoming apparent that a signifi-
cant proportion of common, but unex-
plained, diseases (e.g., the epilepsies,
as well as other neurological and non-
neurological conditions) may be a collec-
tion of rare and often private genomic
disorders due to mutations in genetically
intolerant genes (Petrovski et al., 2013).
The International League Against Epilepsy
classification of epilepsy includes infor-
mation about seizure type, age of onset,
response to antiepileptic drugs, electro-
encephalogram (EEG) and structural
brain imaging information, and prognostic
considerations. From a molecular and
physiological perspective, however, it is
clear that this scheme often bears little
relationship with underlying biology.
Copy-number variants are associated
with a range of epilepsy subtypes (Hein-
zen et al., 2010), including focal epilepsy,
which responds to surgery (Catarino et al.,
2011); causal mutations in SCN1A show
very complex genotype-phenotype rela-
tionships (Zuberi et al., 2011); and muta-
tions in the gene encoding DEPDC5 are
responsible for a significant proportion
of cases of familial nonlesional focal epi-
lepsy (Dibbens et al., 2013).
The National Academies has recently
recognized the need for ‘‘a new taxonomy
of human disease based on molecular
biology’’ in its publication Toward Preci-
sion Medicine (National Research Council
(US) Committee on A Framework for
Developing a New Taxonomy of Disease,
2011). NGS can facilitate individualized
molecular diagnoses in patients and
families with hitherto undiagnosed and
unexplained disorders. The traditional
diagnostic model in the evaluation of
an individual with a putative genetic
disorder includes formulation of a diag-
nostic hypothesis that may include
a diverse range of possibilities. These
possible diagnoses are then tested by
a variety of biochemical (blood, urine,
cerebrospinal fluid [CSF]), structural
(MRI), functional (EEG), and specific
gene analyses. A recent study examined
the economic implications of WES-based
diagnosis in the context of 500 patients
evaluated using traditional genetic tests
(Shashi et al., 2013). This work showedlsevier Inc.that if the diagnosis is not clinically
apparent at the first visit, then the cost
on average per successful genetic diag-
nosis using traditional tests is approxi-
mately $25,000. The cost of WES, on the
other hand, is now well under $1,000 per
sample. Thus, when used in an appro-
priate setting, WES has the potential to
provide significant cost benefit to the
healthcare budget and to society.
Diagnostic sequencing should, and
probably will, find wide, immediate appli-
cation in the care of patients with neuro-
logical disease. The realization of its
full potential will require addressing a
number of key bottlenecks. Of particular
importance is the challenge of data inte-
gration. Clearly, to maximize the benefit
of WES-based diagnostics, it is critical
to be able to compare the sequences of
patients evaluated in different academic
medical centers. In this regard, it is
increasingly clear that communication
among affected families via social media
is hastening the identification of novel
causative variants, and this is a move-
ment that should be fully embraced by
the academic and clinical communities.
For example, a recessive mutation in
NGLY1, encoding N-glycanase, was
recently discovered in a single family as
a cause of a new disorder of deglycosy-
lation (Need et al., 2012). Subsequent
to this initial work, the efforts of that
family were instrumental in the identifica-
tion of further cases (http://matt.might.
net/articles/my-sons-killer/) to confirm
the putative diagnosis. There are also
current plans to initiate and establish
secure sequence data repositories to
allow more dynamic evaluation of patient
genomes than is afforded by the current
diagnostic models.
There are other hurdles and challenges
along the way, but these are sur-
mountable (Cavalleri and Delanty, 2012).
For example, recent bioinformatic ap-
proaches that integrate gene-level and
variant-level prioritization schemes (Pet-
rovski et al., 2013) open the possibility
of identifying candidate mutations in a
genome-wide context, even without prior
information implicating specific genes.
Another issue is that relevant healthcare
professionals often lack the necessary
genomics expertise to counsel patients;
however, this could and should be
addressed through the integration of
Neuron
NeuroViewgenomic medicine into relevant curricula
at the level of theoretical instruction
and also including practical clinical expo-
sure in medical instruction and allied
educational programs. A greater chal-
lenge will be to persuade contemporary
clinicians of the power of clinical geno-
mics. Other challenges include the use
and appropriate release of incidental
data, secure storing of genomic and
updated phenotypic information on an
electronic patient record, appropriate
reimbursement, and—as genetic dis-
coveries continue to be made—a system
for regular reanalysis of genetic variants
after the initial analysis of the patient’s
genome. The latter will become particu-
larly relevant, as the secure interpreta-
tion of disease-causing rare variants will
improve with the availability of increasing
cohorts of control samples from different
populations.
In summary, despite the challenges, it is
now likely that most patients with serious
neurological diseases will soon have
their genomes sequenced, certainly in
the context of pediatric presentations. In
some therapeutic areas, this will mean
that many, and eventually perhaps most,
patients seen will have an identified ge-
netic cause of their condition. Ongoing
efforts to sequence and understand large
cohorts of well-phenotyped individuals,
such as the Epi4K project in epilepsy,
will help lead us to this goal (Epi4K Con-
sortium, 2012). The clinical implications
of these advances are hard to overstate.
First, many more families would have
a diagnosis, which is simply better
medicine than what is currently offered.
Moreover, evaluating appropriate treat-
ments may in some cases be predictedby functional assays in laboratory models
of particular genetic defects instead of
through trial and error in the patient.
Finally, NGS may bridge the divide
between evidence-based medicine and
patient-oriented care and help rehuman-
ize clinical medicine. In an era in which
physicians are being encouraged to see
ever more patients using a formulaic,
protocol-driven approach within a pre-
determined timescale, NGS reminds us
of the unique biology of our patients and
the need to treat each of them as an
individual.REFERENCES
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